Siren Biotechnology has been on a slow drip of regulatory wins for sixteen months now.

First IND clearance in January.

Fast Track in February.

UCSF investigator-IND for the Phase 1 in March.

Each press release said the same thing about the mechanism: SRN-101 is an AAV-based therapy that delivers an “immunomodulatory cytokine” to the tumor microenvironment.

Okay…which cytokine?

Nicole?!? Tell me! I have to know!

Crickets…

Well, that changed today.

Ahead of ASGCT 2026, Siren disclosed its long-awaited preclinical data for its Universal AAV Immuno-Gene Therapy platform. Buried in the release: SRN-101 is an AAV9 vector delivering interferon-beta.

[annndddddd exhale]

This makes a lot of sense and – for the unfamiliar – it’s a bigger deal than it sounds.

Systemic IFNβ as a cancer therapy has a long, mostly painful history. Toxicities. Short half-life. Off-target effects all over the body.

The drug class basically got shelved for oncology in favor of pretty much anything else.

Siren’s bet is that the failure of IFNβ wasn’t IFNβ. It was the delivery.

The plan?

Skip the IV, encode IFNβ inside an AAV9 capsid, inject it directly into the glioma.

The genuis behind this is that, AAV doesn’t integrate into the genome, so cytokine expression continues only as long as living tumor cells are around to host it.

In other words: as the tumor cells die…the cytokine expression dies with it. The tumor self-limits the dose.

It’s a clever twist.

The preclinical data Siren teased today claims tumor regression, prolonged survival, and immune activation in glioma organoids and mouse models. No quantitative numbers in the release itself. Those will likely come at ASGCT.

Here’s another thing:

The platform is “universal” in that the same AAV architecture is supposed to work across multiple solid tumors. Eye and brain are the obvious starts because you can inject directly into the lesion.

Beyond that? Skin cancers? Who knows.

Other pure “AAV in oncology” approaches include: Vironexis and Trogenix (recently covered in a The Biotech Voyager article).

Phase 1 readout from Butowski’s group at UCSF is the next milestone. Whenever it lands, it’ll tell us whether AAV-IFNβ is real, or whether interferon-beta is just bad at being a cancer drug no matter how you deliver it.